Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment publishing date : 2021 - 06 - 28 save search
Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis
Published: 2021-06-28 (Crawled : 20:00) - globenewswire.com
ENTX | $2.195 -1.13% 18K
|
Health Technology
|
| O: -0.66%
H: 0.36%
C: -4.15%
AMGN | $265.52 0.55% 210K
|
Health Technology
|
| O: 0.16%
H: 0.3%
C: -0.31%
treatment phase 2 bone phase 2 results results eb613 conference osteoporosis
SLE-UPDATE Study Finds Reducing Pain, Fatigue, and Flares are Top Treatment Goals for People with Lupus
Published: 2021-06-28 (Crawled : 17:00) - prnewswire.com
LLY | News | $748.11 -0.35% 190K
|
Health Technology
|
| O: -0.53%
H: 0.38%
C: -0.34%
treatment lupus
Crinetics Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
Published: 2021-06-28 (Crawled : 13:15) - crinetics.com
CRNX | $44.04 0.07% 16K
|
Health Technology
|
| O: 1.53%
H: 1.41%
C: -1.2%
treatment phase 3
Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis
Published: 2021-06-28 (Crawled : 12:00) - ir.hoththerapeutics.com
HOTH | $1.23 2.1K
|
Health Technology
|
| O: 1.26%
H: 4.97%
C: -1.86%
treatment phase 1 positive results dermatitis trial atopic dermatitis phase 1b al001 adi-001 phase 2b
SNDX-5613 Granted FDA Fast Track Designation for the Treatment of Relapsed/Refractory Acute Leukemias
Published: 2021-06-28 (Crawled : 12:00) - biospace.com/
SNDX | $20.53 -1.01% 250K
|
Health Technology
|
| O: 4.25%
H: 2.09%
C: -5.49%
treatment fda fda fast track fast track leukemia fast track designation granted grant designation
Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
Published: 2021-06-28 (Crawled : 12:00) - biospace.com/
CRNX | $44.04 0.07% 16K
|
Health Technology
|
| O: 1.53%
H: 1.41%
C: -1.2%
treatment phase 3
Agios Submits Marketing Authorisation Application to European Medicines Agency for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
Published: 2021-06-28 (Crawled : 12:00) - biospace.com/
AGIO | $29.22 0.65% 38K
|
Health Technology
|
| O: 1.32%
H: 0.35%
C: -2.4%
treatment europe application
Rockwell Medical, Inc. Files Pre-IND Meeting Request with FDA for its Proposed Clinical Trial of FPC as a Treatment for Iron Deficiency Anemia in Patients Receiving Home Infusion
Published: 2021-06-28 (Crawled : 12:00) - biospace.com/
RMTI | $1.48 57K
|
Health Technology
|
| O: 3.06%
H: 4.26%
C: 2.14%
treatment fda iron deficiency anemia trial
Adamis Sends Letter to Stockholders Regarding Its Strategic Focus on Tempol as a Potentially Potent Treatment for COVID-19
Published: 2021-06-28 (Crawled : 12:00) - biospace.com/
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 0.81%
H: 3.23%
C: -3.23%
covid treatment potential
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients with Parkinson’s Disease Dementia
Published: 2021-06-28 (Crawled : 12:00) - anavex.com
AVXL | $4.02 -1.23% 180K
|
Health Technology
|
| O: 20.0%
H: 6.06%
C: -2.83%
disease treatment phase 2 dementia correlation parkinson life science trial anavex®2-73 anavex biomarkers
Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction
Published: 2021-06-28 (Crawled : 06:00) - globenewswire.com
ATRS | $5.59 0.0%
|
Health Technology
|
| O: 0.23%
H: 1.84%
C: -1.61%
treatment phase 3
Gainers vs Losers
| 73% | 27% |
Top 10 Gainers
TIRX | $1.13 133.09% 44M
|
AGBA | $0.8978 124.45% 60M
|
Finance
BPTH | $6.18 90.74% 39M
|
Health Technology
INVO | $1.445 90.13% 2.5M
|
Health Technology
SINT | $0.0588 57.64% 240M
|
Health Technology
XPON | $2.66 37.82% 5.2M
|
THCH | $1.38 32.69% 9.9M
|
n/a
ALRN | $5.605 31.88% 210K
|
Health Technology
VTNR S | $1.25 27.66% 3.2M
|
Industrial Services
LRHC | News | $2.02 26.25% 230K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.